




# Dactinomycin

NOT RECOMMENDED AS AN  
ESSENTIAL MEDICINE

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

		EMLc	ATC codes: <b>L01DA01</b>
Indication	Unspecified malignant neoplasms of ill-defined or unspecified sites	ICD11 code: <b>2D9Z</b>	
INN	Dactinomycin		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 500 µg in vial powder for injection		
EML status history	First added in 1984 ( <a href="#">TRS 722</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Removed in 2015 ( <a href="#">TRS 994</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Wikipedia	<a href="#">Dactinomycin</a> 		
DrugBank	<a href="#">Dactinomycin</a> 		

## Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of bleomycin was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for bleomycin for more information.

